Evidence map›Paper›PMID 35776258›Full record

ArticleAnnals of surgical oncology2022

Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer.

Meghan R Flanagan, David R Doody, Jenna Voutsinas, Qian Wu, Kalyan Banda, Nima Sharifi, Christopher I Li, Vijayakrishna K Gadi

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Serendipity, steroids and science.The Journal of steroid biochemistry and molecular biology · 2026
    Review
  2. International journal of molecular sciences · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. BMX controls 3βHSD1 and sex steroid biosynthesis in cancer.The Journal of clinical investigation · 2023
    Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Meghan R FlanaganBreast Section, Department of Surgery, University of Washington, Seattle, WA, USA. mrf22@uw.edu.ORCID http://orcid.org/0000-0002-2330-6374
David R DoodyDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jenna VoutsinasClinical Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Qian WuClinical Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kalyan BandaDivision of Medical Oncology, University of Washington, Seattle, WA, USA.
Nima SharifiDepartment of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Christopher I LiDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Vijayakrishna K GadiDepartment of Hematology and Oncology, University of Illinois Chicago, Chicago, IL, USA.
Fred Hutch Cancer Center · USCleveland Clinic · USUniversity of Illinois Chicago · USUniversity of Washington · USUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHomozygous inheritance of a single-nucleotide polymorphism (1245A > C) in HSD3B1 results in an adrenal permissive phenotype of increased adrenal steroid precursor conversion to potent androgens. This is associated with poor outcomes in prostate cancer. We hypothesized that inheritance of the HSD3B1 adrenal permissive genotype would similarly negatively impact breast cancer outcomes. PATIENTS AND

methodsGermline HSD3B1 was sequenced in 644 postmenopausal women diagnosed between 2004 and 2015 with stage I-III estrogen receptor-positive (ER

resultsAdrenal restrictive genotype (homozygous wild type) was most prevalent (47%), followed by heterozygous (44%) and adrenal permissive (9%). There were no significant differences comparing demographic, tumor, or treatment characteristics apart from higher frequency of adrenal permissive genotype among non-Hispanic white participants (p = 0.04). After accounting for competing risks, the cumulative incidence of distant metastatic recurrence (15 events) was significantly higher among participants with adrenal permissive compared with the adrenal restrictive genotype (HR 4.9, 95% CI 1.32-18.4, p = 0.02). The adrenal permissive genotype was also predictive of breast cancer-specific mortality (HR 3.5, 95% CI 1.27-9.59, p = 0.02).

conclusionsInheritance of the HSD3B1 adrenal permissive genotype is associated with increased incidence of distant metastasis and higher cause-specific mortality in postmenopausal ER

Indexed as

Breast NeoplasmsMultienzyme ComplexesPostmenopauseProgesterone ReductaseSteroid IsomerasesAndrogensEstrogensFemaleGenotypeHumansPolymorphism, Single NucleotideReceptors, Estrogen3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomeraseAndrogensEstrogensMultienzyme ComplexesProgesterone ReductaseReceptors, EstrogenSteroid Isomerases

Identifiers

PMID35776258
OpenAlexW4283760414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.